CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Kadmon Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Kadmon Holdings Inc
450 E 29th St
Phone: (212) 308-6000p:212 308-6000 NEW YORK, NY  10016  United States Fax: (302) 636-5454f:302 636-5454
This company was Merged or Acquired on 11/9/2021.
This company ceased filing statements with the SEC on 11/19/2021.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Kadmon Holdings, Inc. is a biopharmaceutical company, which is engaged in discovering, developing, and delivering therapies for unmet medical needs. The Company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. It is developing oral small molecule inhibitors of Rho-associated coiled-coil kinase (ROCK) to treat immune and fibrotic diseases. Its advanced product candidate, Belumosudil (KD025) is an orally administered, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2). The Company has a biologics research platform focused on the development of immuno-oncology therapeutics, specifically, IL-15-containing fusion proteins for the treatment of cancer. Its advanced candidate from the biologics platform, KD033, is an anti-PD-L1/IL-15 fusion protein designed to stimulate an immune response directed to the tumor microenvironment. IL-15 is a cytokine that expands key tumor-fighting immune cell types.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202112/31/2020YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Non-Executive Chairman of the Board Tasos G.Konidaris 54 1/1/2019 2/1/2017
President, Chief Executive Officer, Director Harlan W.Waksal 67 8/1/2014 1/1/2013
Chief Financial Officer, Executive Vice President StevenMeehan 56 2/8/2019 1/1/2017
7 additional Officers and Directors records available in full report.

Business Names
Business Name
Kadmon I, LLC
Kadmon Pharmaceuticals, LLC
Three Rivers Pharmaceuticals

General Information
Number of Employees: 127 (As of 12/31/2020)
Outstanding Shares: 178,521,071 (As of 10/29/2021)
Shareholders: 187
Stock Exchange: NASD
Federal Tax Id: 273576929
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, November 4, 2024